Prostate Cancer Program

前列腺癌计划：综述 前列腺癌(PR)计划的使命是减少与以下疾病相关的发病率和死亡率 通过在生物学、临床和人口水平上对前列腺癌有深入的了解。 该计划通过跨学科的研究来实现这一使命，这些研究具有高度的协作性和 翻译过来的。自上次竞争性更新以来，战略规划进程导致制定了三个 新的跨学科主题： 主题1：前列腺癌的生物学和分子驱动因素的发现 主题2：预测前列腺癌患者预后的生物标记物和预后模型开发 主题3：开发治疗干预措施以改善前列腺癌患者的预后 公关计划：关键指标 会员(10个系，1所学校)37 整整24小时 助理13 与癌症相关的资金(截至 13,878,515美元 2017/05/31) NCI$5,543,247 40% 同行评审5,289,510美元38% 非同行评审3,045,758美元22% 癌症相关出版物(2012/1-7/2017)616 方案间方案间160 26% 方案内257 42% 高影响力198 32% 临床试验应计费用(2016)923 46 治疗性99 20 其他干预性416 12 非干预性408 14

Prostate Cancer Program: Summary The mission of the Prostate Cancer (PR) Program is to reduce the morbidity and mortality associated with Prostate Cancer by leveraging a deep understanding of the disease at a biologic, clinical, and population level. The Program approaches this mission with transdisciplinary research that is richly collaborative and translational. Since the last competitive renewal, a strategic planning process led to the development of three new transdisciplinary themes: Theme 1: Discovery of Biologic and Molecular Drivers of Prostate Cancer Theme 2: Biomarker and Prognostic Model Development to Predict Outcomes in Men with Prostate Cancer Theme 3: Developing Therapeutic Interventions to Improve Outcomes for Men with Prostate Cancer PR Program: Key Metrics Membership (10 departments, 1 school) 37 Full 24 Associate 13 Cancer-relevant Funding (direct costs as of $13,878,515 05/31/2017) NCI $5,543,247 40% Peer-reviewed $5,289,510 38% Non-peer-reviewed $3,045,758 22% Cancer-relevant Publications (1/2012-7/2017) 616 Inter-programmatic 160 26% Intra-Programmatic 257 42% High-Impact 198 32% Accruals to Clinical Trials (2016) 923 46 Therapeutic 99 20 Other Interventional 416 12 Non-interventional 408 14